Science4Data Article Insights

https://us.gsk.com/en-us/media/press-releases/gsk-announces-new-data-presentations-from-the-dreamm-programme/

GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma

2020-06-05 13:21:29, , source

Content Categorization
/Health/Health Conditions/Cancer
/Business & Industrial/Pharmaceuticals & Biotech

Word Count:
1574

Words/Sentence:
13

Reading Time:
15.74 min

Reading Quality:
Advanced

Readability:
16th or higher

Media Sentiment
Proprietary sentiment analysis on both the headline and body text of the article. Sentiment scores range from -1 (very negative sentiment) to 1 (very positive sentiment).
RCS Analysis
Relative scoring for Risk, Crisis, and Security language within the article.
Risk Score
Scoring based on the composite risk, security and crisis language within an article compared to a baseline of historic analysis across thousands of diverse articles.
PESTEL Scope
Analysis of article orientation across the PESTEL macro-environmental analysis framework. Learn more about PESTEL.
Entity Word Cloud
Key people, places, organizations and events referenced in the article, weighted by frequency and colored based on contextual sentiment.
Auto Summary
Condensing key features of the article based on salience analysis. Helpful for “gisting” the article in a time crunch.

DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to PIs, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs

DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

We are proud to present data at EHA from our extensive DREAMM clinical trial programme as we continue to advance belantamab mafodotin in various relapsed/refractory multiple myeloma treatment settings."

Belantamab mafodotin is an investigational humanised, anti-BCMA (antibody-drug conjugate against B-cell maturation antigen).[1]

DREAMM-3: A Phase III, Open-label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pom/Dex in Relapsed/Refractory Multiple Myeloma (RRMM)

DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma RRMM-Outcomes by Prior Therapies

Keywords

Interested in Learning More?

Article Analysis is at the foundation of powerful media monitoring and insights. Learn what you can build with powerful curated search engines, real-time listening and trend analysis on the topics, markets and companies critical to your organization.